$4.71
-0.41-7.92%
At close: -
$5.12
0.418.62%
After Hours: May 21, 12:15 AM EDT
Comments
Loading...
Latest Innovent Biologics Stock News | OTC:IVBXF | Benzinga
Get the latest news on Innovent Biologics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Innovent Biologics performance
Categories: All
Thursday, August 04, 2022
Thursday, April 14, 2022
Wednesday, April 06, 2022
Thursday, March 24, 2022
Friday, February 11, 2022
Tuesday, September 28, 2021
Friday, August 27, 2021
Monday, August 16, 2021
Friday, August 06, 2021
Friday, July 09, 2021
Thursday, June 03, 2021
Tuesday, May 18, 2021
Wednesday, February 03, 2021
- Innovent and Lilly Jointly Announced the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
- Eli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer